Bangladesh Court Upholds Ruling Barring 34 Drugmakers from Manufacturing Therapies

A Bangladesh high court sustained a ruling from last year that barred 20 drugmakers from manufacturing therapies because of substandard production.

The court upheld the order, which barred drugmakers — including Bikalpa Pharmaceutical, Dolphin Pharmaceuticals, Drugland, Exim Pharmaceutical, Globe Laboratories, Jalpa Laboratories and Kafina Pharmaceuticals — from manufacturing products after holding a hearing on the injunction.

The order also requires that 14 other drugmakers no longer manufacturer antibiotics. The companies include Belsen Pharmaceuticals, Bengal Drugs and Chemicals, Bristol Pharma, Crystal Pharmaceuticals, Indo-Bangla Pharmaceuticals and Millat Pharmaceuticals.